Navigation Links
Skin Medication Matrix Targets Venous Leg Ulcer Healing in New USA Clinical Trial
Date:9/22/2017

The effectiveness of a new wound healing skin medication for venous leg ulcers is now being assessed in clinical trials in the United States. (clinicaltrials.gov : NCT02973893)

To find out more about this clinical trial please talk to your nurse or physician or find your nearest participating clinic here https://factor-therapeutics.com/clinical-trials/ and discuss your condition with one of the medical team.

The new treatment, VF001-DP, is a synthetic skin medication that attaches to the base of the ulcer and creates a microscopic scaffold matrix which encourages the body’s skin cells to move into the wound and regrow skin layers.

Venous ulcers account for 70%–90% of ulcers found on the lower leg, and cost the health system $3.5 billion each year.

Up to one-third of all patients with venous ulcers have recurring wounds, some up to four or more times.

Most sufferers are over 40 years old and are cared for in more than 1,000 out-patient wound care centers in the United States.

The clinical trial, VF00102, is open to 168 people over the age of 18 with non-healing venous ulcers who meet the eligibility criteria – these include:
1. a small ulcer (approx. size of a Dime) that has been there for more than 6 months; or
2. a larger one that has been there for less than 6 months

The company, Factor Therapeutics Limited (ASX:FTT), previously ran a 53-patient trial where one-third of the ulcers healed in 12 weeks, with another half reducing in size by at least 70 per cent.

Participants will have a two-week screening period, then randomised patients will be treated weekly for 12 weeks, with a 12-week follow-up period. All patients enrolled in the study will also receive high quality standard care as part of the trial.

To find out more about this clinical trial please talk to your nurse or physician or find your nearest participating clinic here https://factor-therapeutics.com/clinical-trials/ and discuss your condition with one of the medical team.

Qualified participants will receive all trial related care and financial compensation for time and travel. No insurance is required.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14716475.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. In Focus with Martin Sheen Showcasing How Medication is Helping Win the Fight Against Mood Disorders
2. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
3. Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
4. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
5. National Institute on Drug Abuse Awards SRI International Contract to Test Safety of Medications for Treatment of Substance Abuse
6. Elsevier Delivers Unified Medication Management Platform in China
7. Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication
8. Ten-year study highlights sleep deficiency and sleep medication use in astronauts
9. Increasing Per Capita Spends on Pet Healthcare Drives the Global Animal Medication Market, According to New Report by Global Industry Analysts, Inc.
10. Lawrence Livermore National Laboratory Partners with UC Davis to Personalize Cancer Medications
11. Proove Biosciences Launches World’s First Test to Predict Responders to Opioid Pain Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):